![]() ![]() Therefore, it remains unclear which bronchodilator, LABA or LAMA, is more suitable for the initial treatment of stable COPD. However, this is only due to two head-to-head comparison studies which showed the superiority of tiotropium to salmeterol or indacaterol in preventing exacerbations. On the other hand, in group C and D patients that have experienced exacerbations of COPD, LAMA is more often recommended as a single initial therapy than LABA. According to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) report 2019, there is no mention which bronchodilator, LABA or LAMA, is superior for the initial relief of the symptoms in the GOLD grade group A and B patients. Now, either LABA or LAMA is first used for the treatment of patients with stable COPD. Currently available LAMA comprises tiotropium, glycopyrronium, aclidinium and umeclidinium and LABA includes salmeterol, formoterol, indacaterol, vilanterol and olodaterol. In addition, these bronchodilators improve exercise performance. ![]() Regular daily use of either a long-acting beta-agonist (LABA) or long-acting muscarinic antagonist (LAMA) has been shown to improve the lung function, dyspnea and health status and reduce exacerbations. For the treatment of stable COPD patients, inhaled bronchodilators play a central role in reducing symptoms and exacerbations. The most common symptoms include dyspnea, cough and sputum production, with the symptoms worsening during exacerbations. The Creative Commons Public Domain Dedication waiver ( ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.Ĭhronic obstructive pulmonary disease (COPD) is currently the third leading cause of death in the world. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |